antibodies

News

Non-profit DNDi preps phase 3 trials for dengue antibody

Non-profit DNDi has licensed a dengue therapy from India's SII, paving the way for a phase 3 trial in Malaysia, Thailand, and Brazil.

News

Welsh firm Antiverse raises funds for AI antibody platform

Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.

News

Chai raises $130m for AI drug discovery platform

AI specialist Chai Discovery has said it is sitting on a valuation of around $1.3 billion, after raising $130 million in a Series B financing.

News

Epsilogen buys rival cancer antibody firm TigaTx

Epsilogen has bought TigaTx, pooling their resources to create what it says will be a leader in 'pan-isotope' cancer antibodies.

News

Roche taps Oxford BioTherapeutics for cancer drug discovery

Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.

News

J&J abandons work with Genmab on Darzalex successor

Genmab is facing increased pressure to deliver on its in-house pipeline after Johnson & Johnson exited a partnership on a Darzalex follow-up.

Non-profit DNDi preps phase 3 trials for dengue antibody

Welsh firm Antiverse raises funds for AI antibody platform

Chai raises $130m for AI drug discovery platform

Epsilogen buys rival cancer antibody firm TigaTx

Roche taps Oxford BioTherapeutics for cancer drug discovery

J&J abandons work with Genmab on Darzalex successor

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

antibodies

Editor's Picks